A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-AGT01 RVR in Adult Healthy Volunteers
Latest Information Update: 19 Dec 2024
Price :
$35 *
At a glance
- Drugs Zilebesiran (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 12 Dec 2024 Planned primary completion date changed from 5 Aug 2025 to 8 Sep 2025.
- 12 Dec 2024 Status changed from not yet recruiting to recruiting.
- 08 Nov 2024 New trial record